Icatibanto Stada

Icatibant, the active ingredient in Icatibanto Stada, is a bradykinin B2 receptor antagonist presented as a sterile solution for subcutaneous use. It is indicated for the treatment of hereditary angioedema in patients with C1‑inhibitor deficiency, providing rapid relief of swelling episodes and is currently manufactured under strict EU quality standards.

GNH USA supplies Icatibanto Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established logistics for temperature‑controlled shipment and regulatory support across multiple regions.

Icatibant is used to target bradykinin‑mediated pathways in hereditary angioedema, reducing swelling and associated symptoms.

Hereditary angioedema (C1‑inhibitor deficiency): provides rapid relief of acute swelling episodes. Hereditary angioedema attacks (laryngeal, abdominal, peripheral): reduces airway obstruction risk and abdominal pain. Hereditary angioedema prophylaxis: decreases frequency of recurrent attacks.

Common Side Effects: - Injection site pain or erythema. - Local swelling or induration. - Nausea or mild gastrointestinal discomfort. - Headache. - Dizziness. - Transient fatigue.

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions. - Angioedema unrelated to hereditary episodes. - Severe hypotension. - Thrombocytopenia. - Infections at the injection site. - Cardiovascular events such as myocardial infarction (very rare).

Before initiating therapy, consider patient history and monitor for adverse reactions. - Hypersensitivity assessment: evaluate for known allergy to icatibant or excipients. - Anaphylaxis vigilance: observe for signs of severe allergic response after injection. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Renal or hepatic impairment: no specific dose adjustment, but monitor clinical response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with drugs that influence bradykinin levels or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: can increase bradykinin and heighten risk of angioedema. - Neprilysin inhibitors: elevate bradykinin concentrations, potentially reducing icatibant efficacy. - Other bradykinin‑enhancing agents: may exacerbate swelling.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may modestly increase angioedema risk. - NSAIDs: can aggravate hypersensitivity reactions. - Diuretics: monitor blood pressure due to possible additive hypotensive effect.